HMPL-415 / Hutchmed - LARVOL DELTA

A Multicenter, Open-Label Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients with Advanced Malignant Solid Tumors (ChiCTR) - P1 | N=66 | Recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New P1 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF • EGFR • HER-2 • KRAS

Preclinical characterization of HMPL-415, a second-generation SHP2 inhibitor. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Oncology

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Recruiting | Sponsor: Hutchmed | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • KRAS

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China (GlobeNewswire) - "HUTCHMED (China) Limited...announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective allosteric inhibitor targeting Src homology-2 domain-containing protein tyrosine phosphatase-2 ('SHP2'). The first patient received their first dose on July 6, 2023. The clinical trial is a multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-415 as a single agent in patients with advanced malignant solid tumors. This study is expected to enroll up to approximately 80 patients, including patients as part of the dose escalation stage, and further patients at the determined recommended Ph II dose (RP2D)."

Trial status • Oncology • Solid Tumor

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Not yet recruiting | Sponsor: Hutchmed

Metastases • New P1 trial • Oncology • Solid Tumor • KRAS